ELAHERE has a well-established safety profile to help YOU support your patients through treatment

Adverse REACTIONS reported in ≥10% of patients receiving ELAHERE in SORAYA1

Adverse reaction (N=106)1

*Blurred vision includes vision blurred, vitreous floaters, visual acuity reduced, diplopia, presbyopia, accommodation disorder, visual impairment, and refraction disorder.1

†Keratopathy includes corneal disorder, corneal epithelial microcysts, corneal epithelial defect, keratitis, keratopathy, corneal deposits, and punctate keratitis.1

‡Dry eye includes dry eye and lacrimation increased.1

§Eye pain includes eye pain and ocular discomfort.1

Fatigue includes fatigue and asthenia.1

#Abdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, abdominal discomfort.1

||Peripheral neuropathy includes neuropathy peripheral, peripheral sensory neuropathy, peripheral motor neuropathy, paresthesia, hypoesthesia, polyneuropathy, and neurotoxicity.1

**Dyspnea includes dyspnea and exertional dyspnea.1

Infusion bag with down arrow icon

Dosage delays of ELAHERE due to an AR occurred in 39% of patients. ARs that required dosage delays in ≥3% of patients included1:

  • Blurred vision (15%)
  • Keratopathy (11%)
  • Neutropenia (6%)
  • Dry eye (5%)
  • Cataracts (3%)
  • Increased gamma-glutamyl transferase (3%)
Serious icon

Clinically relevant ARs occurring in <10% of patients who received ELAHERE in SORAYA included1:

  • Infusion-related reactions/hypersensitivity (9%)
  • Pneumonitis (8%)
  • Uveitis (1%)
Down arrow icon

Dose reductions of ELAHERE due to an AR occurred in 20% of patients1

  • ARs that required dose reductions in ≥3% of patients included blurred vision (9%) and keratopathy (7%)
Hazard icon

Serious ARs occurred in 31% of patients. The most common (≥2%) serious ARs were1:

  • Intestinal obstruction (8%)
  • Ascites (4%)
  • Infection (3%)
  • Pleural effusion (3%)
Discontinuation icon

Permanent discontinuation due to ARs occurred in 11% of patients1

  • The most common (≥2%) ARs leading to permanent discontinuation were intestinal obstruction (2%) and thrombocytopenia (2%)
  • One patient (0.9%) permanently discontinued ELAHERE due to visual impairment (unilateral decrease to BCVA ≤20/200 that resolved to baseline after discontinuation)
Calendar icon

The median duration of treatment was 4.2 months (range: 0.7 to 13.3)1

AR=adverse reaction; BCVA=best corrected visual acuity.

Laboratory abnormalities in SORAYA

Select laboratory abnormalities ≥10% for all grades or ≥2% for Grades 3-4 in patients who received ELAHERE

Laboratory abnormalities for ELAHERE

ALT=alanine aminotransferase; AST=aspartate aminotransferase.

*The denominator used to calculate the rate varied from 98 to 101 based on the number of patients with a baseline value and at least 1 posttreatment value.1

Resources for treatment

From eye care to access and reimbursement, information is available to support your patients and your practice.

How dose modifications can help

Dose modifications can help manage adverse reactions
and keep patients on treatment.